Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 5/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555401 | 0.79 | TGFBR1 (0.63) | PRKD3TGFBR1PRKD1PRKD2SLC40A1 | |
| SCHEMBL5551427 | 0.77 | PRKD3 (0.48) | PRKD3TGFBR1PRKD1PRKD2NR4A2 | |
| SCHEMBL5551436 | 0.77 | NR1I3 (0.48) | TGFBR1TOP1NR4A2L3MBTL1MAPT | |
| SCHEMBL3110244 | 0.76 | CYP1A2 (0.47) | TOP1METAP1CCR1CCR8L3MBTL1 | |
| SCHEMBL6833300 | 0.73 | KDM4E (0.40) | TOP1NR4A2METAP1CCR1CCR8 | |
| SCHEMBL17445466 | 0.72 | TOP1 (0.50) | TOP1METAP1 | |
| SCHEMBL17445465 | 0.70 | NPC1 (0.41) | TOP1NR4A2METAP1CCR1CCR8 | |
| SCHEMBL29907250 | 0.69 | LMNA (0.43) | TOP1NR4A2METAP1CCR1CCR8 | |
| SCHEMBL1992034 | 0.69 | LMNA (0.43) | TOP1NR4A2METAP1CCR1CCR8 | |
| SCHEMBL13649274 | 0.69 | HTR2B (0.44) | PRKD3TGFBR1PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096333-A1 | Quinazoline derivatives as medicaments | HRH4, HRH2, HRH3 | PRKD3 3011/4885TGFBR1 70/4885PRKD1 3332/4885 |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SMAD3, SMAD2, TGFB2 | PRKD3 1661/4885TGFBR1 8/4885PRKD1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.